Correlation Between Tempest Therapeutics and Biofrontera Warrants

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Tempest Therapeutics and Biofrontera Warrants at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tempest Therapeutics and Biofrontera Warrants into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tempest Therapeutics and Biofrontera Warrants, you can compare the effects of market volatilities on Tempest Therapeutics and Biofrontera Warrants and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tempest Therapeutics with a short position of Biofrontera Warrants. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tempest Therapeutics and Biofrontera Warrants.

Diversification Opportunities for Tempest Therapeutics and Biofrontera Warrants

-0.45
  Correlation Coefficient

Very good diversification

The 3 months correlation between Tempest and Biofrontera is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Tempest Therapeutics and Biofrontera Warrants in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biofrontera Warrants and Tempest Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tempest Therapeutics are associated (or correlated) with Biofrontera Warrants. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biofrontera Warrants has no effect on the direction of Tempest Therapeutics i.e., Tempest Therapeutics and Biofrontera Warrants go up and down completely randomly.

Pair Corralation between Tempest Therapeutics and Biofrontera Warrants

Given the investment horizon of 90 days Tempest Therapeutics is expected to under-perform the Biofrontera Warrants. But the stock apears to be less risky and, when comparing its historical volatility, Tempest Therapeutics is 19.32 times less risky than Biofrontera Warrants. The stock trades about -0.13 of its potential returns per unit of risk. The Biofrontera Warrants is currently generating about 0.23 of returns per unit of risk over similar time horizon. If you would invest  3.90  in Biofrontera Warrants on August 29, 2024 and sell it today you would earn a total of  4.64  from holding Biofrontera Warrants or generate 118.97% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy90.91%
ValuesDaily Returns

Tempest Therapeutics  vs.  Biofrontera Warrants

 Performance 
       Timeline  
Tempest Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Tempest Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Biofrontera Warrants 

Risk-Adjusted Performance

19 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Biofrontera Warrants are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent forward indicators, Biofrontera Warrants showed solid returns over the last few months and may actually be approaching a breakup point.

Tempest Therapeutics and Biofrontera Warrants Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Tempest Therapeutics and Biofrontera Warrants

The main advantage of trading using opposite Tempest Therapeutics and Biofrontera Warrants positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tempest Therapeutics position performs unexpectedly, Biofrontera Warrants can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biofrontera Warrants will offset losses from the drop in Biofrontera Warrants' long position.
The idea behind Tempest Therapeutics and Biofrontera Warrants pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Money Managers
Screen money managers from public funds and ETFs managed around the world
Global Correlations
Find global opportunities by holding instruments from different markets
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance